Raymond James Financial Inc. Purchases Shares of 235,211 Medpace Holdings, Inc. (NASDAQ:MEDP)

Raymond James Financial Inc. acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, Holdings Channel.com reports. The fund acquired 235,211 shares of the company’s stock, valued at approximately $78,144,000.

Other large investors also recently modified their holdings of the company. R Squared Ltd bought a new position in shares of Medpace in the fourth quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace in the fourth quarter valued at about $31,000. Stone House Investment Management LLC bought a new position in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new position in Medpace during the third quarter worth about $37,000. Finally, Jones Financial Companies Lllp increased its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Trading Up 2.2 %

MEDP opened at $332.81 on Monday. The company’s 50 day moving average is $341.10 and its 200-day moving average is $342.93. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The company has a market cap of $10.14 billion, a P/E ratio of 26.35, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

Separately, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.